Pavel Raifeld, Innoviva CEO

Cash-strapped an­tibi­otics play­er En­ta­sis could go pri­vate with a small-dol­lar buy­out of­fer on the ta­ble

It looks like an­tibi­otics play­er En­ta­sis may be get­ting off Nas­daq the same way it ar­rived — with a whim­per.


Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.